Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Events & Presentations Presentation J.P. Morgan 41st Annual Healthcare Conference January 9, 2023 Past Events J.P. Morgan 41st Annual Healthcare Conference Jan 9, 2023 Supporting Materials J.P. Morgan 41st Annual Healthcare Conference 1.3 MB Jefferies London Healthcare Conference Nov 15, 2022 at 4:25 PM GMT Click here for webcast Q3 2022 Invivyd Earnings Conference Call Nov 10, 2022 at 4:30 PM EST Click here for webcast H.C. Wainwright 24th Annual Global Investment Conference Sep 13, 2022 Morgan Stanley 20th Annual Global Healthcare Conference Sep 12, 2022 at 2:50 PM EDT Click here for webcast ASM Microbe 2022 Jun 9 - Jun 13, 2022 Supporting Materials Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB Adagio Therapeutics, Inc. 2022 Annual Meeting of Stockholders May 26, 2022 at 8:30 AM EDT ECCMID 2022 Apr 23 - Apr 26, 2022 Supporting Materials ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants 860.1 KB Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 1.2 MB Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Jan 13, 2022 at 7:30 AM EST Supporting Materials Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Presentation 3.9 MB ISIRV-WHO Conference 2021 Oct 19 - Oct 21, 2021 Supporting Materials (130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19 519.6 KB (131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study 295.1 KB Current page 1 Page 2 Next page next › Last page last »
Presentation J.P. Morgan 41st Annual Healthcare Conference January 9, 2023 Past Events J.P. Morgan 41st Annual Healthcare Conference Jan 9, 2023 Supporting Materials J.P. Morgan 41st Annual Healthcare Conference 1.3 MB Jefferies London Healthcare Conference Nov 15, 2022 at 4:25 PM GMT Click here for webcast Q3 2022 Invivyd Earnings Conference Call Nov 10, 2022 at 4:30 PM EST Click here for webcast H.C. Wainwright 24th Annual Global Investment Conference Sep 13, 2022 Morgan Stanley 20th Annual Global Healthcare Conference Sep 12, 2022 at 2:50 PM EDT Click here for webcast ASM Microbe 2022 Jun 9 - Jun 13, 2022 Supporting Materials Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB Adagio Therapeutics, Inc. 2022 Annual Meeting of Stockholders May 26, 2022 at 8:30 AM EDT ECCMID 2022 Apr 23 - Apr 26, 2022 Supporting Materials ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants 860.1 KB Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 1.2 MB Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Jan 13, 2022 at 7:30 AM EST Supporting Materials Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Presentation 3.9 MB ISIRV-WHO Conference 2021 Oct 19 - Oct 21, 2021 Supporting Materials (130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19 519.6 KB (131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study 295.1 KB Current page 1 Page 2 Next page next › Last page last »
J.P. Morgan 41st Annual Healthcare Conference Jan 9, 2023 Supporting Materials J.P. Morgan 41st Annual Healthcare Conference 1.3 MB
Morgan Stanley 20th Annual Global Healthcare Conference Sep 12, 2022 at 2:50 PM EDT Click here for webcast
ASM Microbe 2022 Jun 9 - Jun 13, 2022 Supporting Materials Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB
Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB
ECCMID 2022 Apr 23 - Apr 26, 2022 Supporting Materials ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants 860.1 KB Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 1.2 MB
ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants 860.1 KB
Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 1.2 MB
Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Jan 13, 2022 at 7:30 AM EST Supporting Materials Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Presentation 3.9 MB
ISIRV-WHO Conference 2021 Oct 19 - Oct 21, 2021 Supporting Materials (130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19 519.6 KB (131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study 295.1 KB
(130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19 519.6 KB
(131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study 295.1 KB
